Altimmune Inc ALT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/27/22 EDT
5.03UNCH (UNCH)
Volume
16,264
Close
5.03quote price arrow up+0.17 (+3.50%)
Volume
500,218
52 week range
3.83 - 19.46
Loading...
  • Open4.89
  • Day High5.17
  • Day Low4.64
  • Prev Close4.86
  • 52 Week High19.46
  • 52 Week High Date06/16/21
  • 52 Week Low3.83
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap217.40M
  • Shares Out43.22M
  • 10 Day Average Volume0.64M
  • Dividend-
  • Dividend Yield-
  • Beta1.42
  • YTD % Change-45.09

KEY STATS

  • Open4.89
  • Day High5.17
  • Day Low4.64
  • Prev Close4.86
  • 52 Week High19.46
  • 52 Week High Date06/16/21
  • 52 Week Low3.83
  • 52 Week Low Date05/12/22
  • Market Cap217.40M
  • Shares Out43.22M
  • 10 Day Average Volume0.64M
  • Dividend-
  • Dividend Yield-
  • Beta1.42
  • YTD % Change-45.09

RATIOS/PROFITABILITY

  • EPS (TTM)-2.41
  • P/E (TTM)-2.08
  • Fwd P/E (NTM)-2.41
  • EBITDA (TTM)-89.503M
  • ROE (TTM)-47.14%
  • Revenue (TTM)3.60M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-2,820.01%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/08/2022(est)
  • Ex Div Date02/06/2017
  • Div Amount2.91
  • Split Date-
  • Split Factor-

Latest On Altimmune Inc

There is no recent news for this security.

Profile

MORE
Altimmune, Inc. is a clinical-stage biopharmaceutical company that is focused on developing treatments for obesity and liver diseases. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). It is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic...
Mitchel Sayare Ph.D.
Independent Chairman of the Board
Vipin Garg Ph.D.
President, Chief Executive Officer, Director
Richard Eisenstadt
Chief Financial Officer
Address
910 Clopper Rd Ste 201S
Gaithersburg, MD
20878-1361
United States

Top Peers

SYMBOLLASTCHG%CHG
VTGN
VistaGen Therapeutics Inc
1.06+0.04+3.92%
COGT
Cogent Biosciences Inc
5.20+0.23+4.63%
PRLD
Prelude Therapeutics Inc
4.57+0.03+0.66%
OMIC
Singular Genomics Systems Inc
3.09+0.23+8.04%
KRON
Kronos Bio Inc
3.69+0.28+8.21%